Breast cancer is the most frequently diagnosed cancer today. Breast cancer mortality in high-income countries significantly dropped, due to advances in diagnostic methods and cancer therapy, as well as implementation of national breast cancer screening programs. Luminal A subtype is the most common immunohistochemical subtype of breast cancer. This study examines histopathological features and treatment approaches in patients with luminal A breast cancer. Study included 72 patients who were diagnostically evaluated in 2020, and subsequently treated in University Hospital Centre Zagreb. Of all patients, 22 patients were premenopausal and 50 patients were postmenopausal. Patients in the sixth and seventh decade represented almost 60% of all patients. All tumors were histologically graded as GI and GII, with no GIII tumors. The frequency of invasive breast carcinoma of no special type (NST) was the highest, while the frequency of lobular cancer and special types was much lower. More than half of premenopausal patients had stage II or III disease. Most postmenopausal patients had stage I disease. Only 2 patients had stage IV disease. Of all patients, only 6 patients were not treated surgically. Omission of radiotherapy after breast conserving surgery was appropriate only in exceptional cases, while omitting radiotherapy after mastectomy was common. The presence of positive axillary lymph nodes was found in 12 patients. Of 22 premenopausal patients, 14 patients were prescribed tamoxifen as initial treatment option, while 8 patients were prescribed goserelin in combination with aromatase inhibitor or tamoxifen. Of 50 postmenopausal patients, 47 patients were prescribed aromatase inhibitors and 3 patients were prescribed tamoxifen. Adjuvant chemotherapy was prescribed to 6 patients, while 11 patients received neoadjuvant treatment. Adjuvant chemotherapy and neoadjuvant treatment were appropriate treatment options for stages II, III and IV. In 3-year followup, 63 patients from the analysed group are alive with no signs of relapse, while 9 patients were lost to follow-up.